Clinical trials: Neoplasms Recurrence
Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04108325
- Testing
- YY-20394
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Multiple Myeloma
IMGN901 in Combination With Lenalidomide and Dexamethasone
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
- Trial name
- NCT00991562
- Testing
- IMGN901
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese…
- Conditions
- Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
- Trial name
- ZIRDOSE-CP (NCT05861778)
- Testing
- 89Zr-Girentuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Advanced Breast Cancer
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
- Trial name
- NCT00328120
- Testing
- Fulvestrant
- Where
- 5 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
- Trial name
- NCT05787496
- Testing
- NC525
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- NextCure, Inc.
Renal Cell Carcinoma
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Multi-Center Randomized Open-Label Study of single agent IMO-2055 Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
- Trial name
- NCT00729053
- Testing
- IMO-2055
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
The purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not previously received any treatment for…
- Trial name
- EGFR (NCT02186301)
- Testing
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Where
- 74 sites in United States, Germany and 5 more
- Volunteers
- 100 people
- Sponsor
- Clovis Oncology, Inc.
Recurrent Glioblastoma
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study.
- Trial name
- REGAL (NCT00777153)
- Testing
- Cediranib, Lomustine Chemotherapy
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Cervical Carcinoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by…
- Trial name
- NCT03108495
- Testing
- LN-145, LN-145 + pembrolizumab
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 210 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
GCT, Giant Cell Tumor of Bone
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.
- Trial name
- NCT00396279
- Testing
- Denosumab, Calcium/Vitamin D
- Volunteers
- 37 people
- Sponsor
- Amgen
Ovarian Cancer
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian…
- Trial name
- NCT06840002
- Testing
- SHR-A1811, Carboplatin, Bevacizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Trial name
- NCT05451810
- Testing
- Epcoritamab
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 184 people
- Sponsor
- Genmab
Solid Tumor, Unresectable or Metastatic Melanoma
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
- Trial name
- NCT03993379
- Testing
- CX-072, Ipilimumab
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- CytomX Therapeutics
Lymphoma, Large B-Cell, Diffuse (DLBCL)
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
NM-IL-12 is being evaluated as an immunotherapeutic with concomitant hematopoietic regenerating properties for treatment of relapsed/refractory DLBCL, an aggressive type of B-cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT02544724
- Testing
- NM-IL-12
- Volunteers
- 12 people
- Sponsor
- Neumedicines Inc.
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Breast Cancer
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA)…
- Trial name
- NCT06401421
- Testing
- ctDNA MRD test
- Where
- 61 sites in United States, Canada
- Volunteers
- 1,800 people
- Sponsor
- Exact Sciences Corporation
Multiple Myeloma (MM), Cancer
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT04178902
- Testing
- ABBV-467
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Relapsed or Refractory B-cell Lymphoma
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
- Trial name
- A-319 (NCT04056975)
- Testing
- Recombinant Anti-CD19m-CD3 Antibody Injection
- Volunteers
- 54 people
- Sponsor
- EVIVE Biotechnology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.